TOP HEADLINES

Editor's Corner

Novo buys U.S. plant ditched by Olympus

Olympus Biologics' loss is Novo Nordisk's gain. This year, Japan-based Olympus gave up on producing regenerative products in the U.S. and put a "reduced" sale price on a plant in New Hampshire, which it said would close by August if it could not find a buyer. August rolled around and Sweden-based Novo swept in with a buy.

Patheon gets U.S. biologics plants with Gallus deal

The big deal in contract manufacturing these days is biologics. Patheon is among those investing in facilities to capture more of that business. Patheon parent DPx has agreed to buy Gallus BioPharmaceuticals, presenting Patheon with its first biologics plants in the U.S.

Merck KGaA starts work on what will be its second-largest plant

Merck KGaA emphasized the importance of China as a market when it announced last year it would build a new plant there, and again last month when it announced it was getting ready to start construction on the facility. And this week, just in case anyone had missed it, the drugmaker said construction had begun on the plant which will make meds on China's essential drug list.

UPDATED: GSK, NewLink ramp up production of Ebola drugs, even as they conduct trials

In an effort to contain the Ebola outbreak in Africa that has already killed more than 1,500 people, companies around the world, including GlaxoSmithKline, are fast-tracking treatments and vaccines to try to get ahead of the disease spread. And in an effort to do that, companies are manufacturing doses, even as they are testing drugs, so that they will have product ready to go ASAP.

Grand River opens new finishing facility

Grand River Aseptic Manufacturing (GRAM), a small parenteral contract manufacturing company in Grand Rapids, MI, has opened a new 28,000-square-foot facility for its finishing operations, inspection services and storage, as well as housing a substantially larger lab, Contract Pharma reports.

MORE NEWS

From Our Sister Sites

FierceBiotech

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some...

FierceBiotech

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma...